TZ9 is a selective and cell permeable inhibitor of human E2 ubiquitin-conjugating enzyme Rad6B. It binds to the Rad6B catalytic site, inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin. It can induce G2/M arrest and apoptosis, and inhibit proliferation and migration of metastatic human breast cancer cells (IC50 ~6 µM).
CAS Number: 1002789-86-7
Molecular Weight: 366.33
Chemical Name: (4-amino-6-(phenylamino)-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate
Appearance: Solid Power.
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO up to 50 mM
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥360 days if stored properly.
Stock Solution Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.
Drug Formulation: To be determined.
HS Tariff Code: 382200
How to use
TZ9 was used at 10-50 µM final concentration in vitro and in cellular assays.
- Sanders MA, et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. (2013) Mol Cancer Ther. 12(4):373-83.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.